# R1 Clinical-Safety Review - aggressive_nk_cell_leukemia

VERDICT: APPROVE

Reviewer: stewardmd-clinical-reviewer (R1, blocking gate)
Confidence: 90
Goldens changed: no (intended: n/a - narrative content, not engine/rule logic)
Adversarial verdict file (.verdict.md): NOT PRESENT at the given path. No prior flags to reconcile.

## 1. Safety
No unsafe, misleading, or absolute directive statements found.
- First-line asparaginase-containing chemotherapy, anthracycline resistance, allo-HSCT for fit responders, HLH-as-emergency, DIC correction (FFP/cryo/platelets), TLS and antimicrobial prophylaxis, serial EBV DNA and ferritin/triglyceride/fibrinogen monitoring - all clinically correct and non-harmful if followed.
- Strong claims are appropriately hedged ("only realistic prospect of durable disease control", "generally individualized", "in consultation with a haemato-oncology/transplant centre"). No claim oversteps decision-support.
- Correctly warns AGAINST extrapolating the RT-based approach from extranodal NK/T-cell lymphoma (nasal type) to ANKL - a genuine safety guardrail against a plausible clinician error.

## 2. Grounding
Grounding integrity is strong and honest.
- The sourcing note explicitly states DeVita 12th ed. carries NO dedicated ANKL management section (only a WHO-classification table entry). This is accurate.
- Every treatment claim is labelled either "general oncology standard, not from DeVita's section on this disease" OR "borrowed from DeVita's chapter on extranodal NK/T-cell lymphoma, nasal type." No claim is mis-attributed to a non-existent DeVita ANKL section. This is exactly the attribution discipline R1 requires.
- The asparaginase-first / anthracycline-resistant-via-efflux content is consistent with accepted standard of care (SMILE-type asparaginase regimens; P-glycoprotein/MDR-mediated anthracycline resistance in NK neoplasms). No fabricated or outdated regimen.

## 3. Dose-free
Confirmed. No mg, mg/m2, AUC, or numbered schedules. Only non-dose numerics are the edition ("12th ed.") and prognostic time descriptors ("weeks to months"). Draft explicitly defers doses to structured protocol templates.

## 4. Scope
Appropriately scoped as decision-support: emphasizes emergent referral, transplant-centre consultation, parallel palliative-care/goals-of-care, individualized relapse management. Not a directive.

## Critical
None.

## Important
None.

## Advisory
- L10 "likely through drug efflux mechanisms" is a mechanistic aside; keep it flagged as general standard (it already is). Fine as-is.
- Consider that the closing "Sources:" line names only DeVita 12th ed. while much of the content is explicitly self-labelled "general oncology standard" (i.e., not DeVita). Not blocking - the inline per-claim labels already prevent mis-attribution - but the trailing single-source line could read as broader endorsement than intended.

Net: clinically safe, honestly grounded with no DeVita mis-attribution, dose-free, appropriately hedged. Approved for the management field.
